A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Administered By

Awarded By

Contributors

Start/End

  • November 23, 2020 - November 26, 2025